First Wave BioPharma, Inc.
Symbol: FWBI
NASDAQ
2.82
USDTrhová cena dnes
-0.2784
Pomer P/E
0.0000
Pomer PEG
5.71M
MRK Cap
- 0.00%
Výnos DIV
First Wave BioPharma, Inc. (FWBI) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10.3 | 3.7 | 1.4 | 8.2 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0.02 | 0 | 0.1 | 0 | ||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-current-assets | 4.49 | 1.2 | 2 | 1176268 | ||||||||||
balance-sheet.row.total-current-assets | 14.82 | 5 | 3.4 | 9.4 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0.98 | 0.2 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.goodwill | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.long-term-investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | -0.06 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.12 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-non-current-assets | 7.86 | 1.9 | 2 | 2.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.account-payables | 3.19 | 0.6 | 0.7 | 2.7 | ||||||||||
balance-sheet.row.short-term-debt | 1.41 | 0.7 | 0.7 | 0.7 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 0.69 | 0.1 | 0.2 | 0.3 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 2.58 | 0.8 | 1.1 | 8 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0.69 | 0.1 | 0.2 | 7.3 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0.89 | 0.1 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.total-liab | 12.2 | 3.3 | 2.7 | 19.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -713.95 | -184.3 | -168.5 | -153.9 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | -1.2 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 724.43 | 187.9 | 171.3 | 147.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22.67 | - | - | - | ||||||||||
Total Investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 2.1 | 0.8 | 0.9 | 1 | ||||||||||
balance-sheet.row.net-debt | -8.2 | -2.9 | -0.5 | -7.2 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
cash-flows.row.depreciation-and-amortization | 0.03 | 0 | 0 | 0.5 | |||||||||
cash-flows.row.deferred-income-tax | -0.17 | 0.2 | 0 | 3.8 | |||||||||
cash-flows.row.stock-based-compensation | 1.04 | 1 | 0.8 | 1.4 | |||||||||
cash-flows.row.change-in-working-capital | 2.19 | 2.2 | -10.5 | 17.1 | |||||||||
cash-flows.row.account-receivables | 0.09 | 0.1 | -0.1 | 0.6 | |||||||||
cash-flows.row.inventory | 0.75 | 0 | 0.1 | -0.6 | |||||||||
cash-flows.row.account-payables | -0.17 | -0.2 | -2 | 1.4 | |||||||||
cash-flows.row.other-working-capital | 1.51 | 2.3 | -8.5 | 15.7 | |||||||||
cash-flows.row.other-non-cash-items | 0.32 | 0 | 2 | 3.5 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -12.38 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.debt-repayment | -0.6 | -0.6 | -0.6 | -507125 | |||||||||
cash-flows.row.common-stock-issued | 9.88 | 15.8 | 23 | 32.7 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 4000000 | |||||||||
cash-flows.row.dividends-paid | 0 | -0.3 | 0 | -4507125 | |||||||||
cash-flows.row.other-financing-activites | 6.04 | 15.4 | -6.6 | 1014262.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 15.23 | 15.2 | 15.7 | 44.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 2.35 | 2.3 | -6.9 | 2.2 | |||||||||
cash-flows.row.cash-at-end-of-period | 10.37 | 3.7 | 1.4 | 8.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 8.02 | 1.4 | 8.2 | 6.1 | |||||||||
cash-flows.row.operating-cash-flow | -12.38 | -12.4 | -22.3 | -32.3 | |||||||||
cash-flows.row.capital-expenditure | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.free-cash-flow | -12.88 | -12.9 | -22.3 | -42.6 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.cost-of-revenue | 0.08 | 0 | 0.1 | 0.5 | |||||||||
income-statement-row.row.gross-profit | -0.08 | 0 | -0.1 | -0.5 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 5.03 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 10.74 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.operating-expenses | 15.76 | 15.7 | 12.7 | 56.7 | |||||||||
income-statement-row.row.cost-and-expenses | 15.77 | 15.8 | 12.7 | 56.7 | |||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.total-operating-expenses | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 0.03 | 0 | -0.2 | 3.4 | |||||||||
income-statement-row.row.ebitda-caps | -15.74 | - | - | - | |||||||||
income-statement-row.row.operating-income | -15.77 | -15.8 | -12.7 | -59.1 | |||||||||
income-statement-row.row.income-before-tax | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
income-statement-row.row.income-tax-expense | 0.02 | 0 | 2 | 0.5 | |||||||||
income-statement-row.row.net-income | -15.81 | -15.8 | -16.6 | -59.1 |
Často kladené otázky
Čo je First Wave BioPharma, Inc. (FWBI) celkové aktíva?
First Wave BioPharma, Inc. (FWBI) celkové aktíva sú 6883195.000.
Aký je ročný obrat podniku?
Ročné príjmy sú N/A.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.000.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -8.250.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.000.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.000.
Aká je First Wave BioPharma, Inc. (FWBI) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -15794983.000.
Aký je celkový dlh firmy?
Celkový dlh je 826844.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 15741553.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 3711770.000.